Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775341 | 0.85 | SLC6A2 (0.74) | SLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL14775025 | 0.76 | SLC6A4 (1.00) | SLC6A2SLC6A3SLC6A4SIGMAR1 | |
| SCHEMBL406357 | 0.75 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4SIGMAR1 | |
| SCHEMBL14775432 | 0.74 | SLC6A4 (0.86) | SLC6A2SLC6A3SLC6A4SIGMAR1 | |
| SCHEMBL6770103 | 0.74 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4SIGMAR1ALDH1A1 | |
| SCHEMBL6206712 | 0.74 | SLC6A2 (0.62) | SLC6A2SLC6A3SLC6A4ALDH1A1GAA | |
| SCHEMBL14775283 | 0.74 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4SIGMAR1 | |
| SCHEMBL14775500 | 0.73 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4SIGMAR1 | |
| SCHEMBL7312748 | 0.73 | SLC6A2 (0.68) | SLC6A2SLC6A3SLC6A4ALDH1A1GAA | |
| SCHEMBL6770099 | 0.73 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570409-B1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-8962621-B2 | Aralkyl diamine derivatives and uses thereof as antidepressants | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-03-21 | — | — | US | disclosed |
| EP-2570409-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | MAOA, SLC6A2, MAOB | SLC6A2 2/4885SLC6A3 4/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.